Stroke SequelaeNCT06121947
Safety and Efficacy Study of Implantable Neuromodulation for Poststroke Hemiplegia
A study testing The DBS electrodes are implanted into MLR. and The electrodes are implanted into the patient's vagus nerve in people with Stroke Sequelae and Deep Brain Stimulation, run by Chinese PLA General Hospital at 1 site in China.
Trial summary
Background: Hemiplegia is a common complication after a stroke. Studies have shown that traditional medical and rehabilitation treatments are not good for improving patients' motor function, deep brain stimulation (DBS) and vagus nerve stimulation (VNS) can improve the motor function of patients, but there is no… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Stroke Sequelae, Deep Brain Stimulation, Vagus Nerve Stimulation
- What is being tested?
- The DBS electrodes are implanted into MLR. and The electrodes are implanted into the patient's vagus nerve
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 98 participants
- Where
- 1 siteChina
- Study dates
- 10 Nov 2023to 30 Oct 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Meet WHO or international diagnostic criteria for stroke disease;
- The first unilateral supratentorial ischemic or hemorrhagic stroke, the condition is stable after acute treatment of ischemic stroke, the course of disease is 6 months ≤ 1 year, and participate in 2 evaluations (screening and baseline) before enrollment.
- Diagnosed by professional physicians combined with brain CT or magnetic resonance imaging and other imaging techniques;
- Between the ages of 18 and 80, male or female
- The responsible lesion in the unilateral white matter area indicated by cranial CT or MRI
- Relevant sequelae such as limb dysfunction after stroke, accompanied by unilateral limb motor dysfunction, proved to be right-handed by standardized examination.
Show all 10Show fewer
- National Institutes of Health Stroke Scale (NIHSS) score from 2 to 20, grades paralyzed muscle strength, between grades 1 and 4, WISCI II, grade >2 (0-20 items): Assisted by one or more persons, able to walk at least 10 m, and less responsive to conventional rehabilitation prior to inclusion.
- Perfect clinical data
- Stable medical and physical condition with adequate nursing support and appropriate medical care in the patient's home community.
- The patient himself or voluntarily signs the informed consent and is willing to cooperate with relevant treatmen
Who cannot join
- Glasgow Coma Scale (GSC) score below 15, Minimum Mental State Examination (MMSE) assessment for dementia indicated, suffering from mental disturbance and unable to cooperate with examination or treatment.
- Motor and sensory disturbances are not induced by stroke, nor by previous ischemic stroke, but stroke induced by trauma, brain tumor, etc.
- Serious comorbidities, such as malignant tumors, primary heart, liver, kidney or hematopoietic system diseases.
- History of cognitive impairment, mental disorder, drug abuse, drug allergy, and alcoholism.
- Infection or rupture of the skin on the forearm or leg.
- Possess a pacemaker, metal stent, plate, or implant susceptible to electrical impulses in the body (pacemaker or defibrillator, baclofen pump, deep brain stimulator, Ventricular shunts, shrapnel, etc.).
Show all 14Show fewer
- Pregnant or breast-feeding or have a recent birth plan.
- IS CLASSROUS.
- Congenital or acquired abnormalities of lower extremities (affecting joints and bones).
- Registration of investigators, their family members, employees, and other dependents.
- Severe joint contractures cause loss or limitation of lower limb activities.
- Blood system diseases with increased risk of bleeding during surgical intervention.
- Participate in another study drug study within 30 days before and during this study.
- Unable to complete the basic process, or difficult to maintain compliance and follow-up
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Chinese PLA General Hospital
Beijing
Zhiqi Mao, PhD, 8618910155994, markmaoqi@126.com
Junpeng Xu, MD, 8613144628367, junpengxv@163.com
About this study
Official title: Comparative Study of the Efficacy and Safety of Deep Brain Stimulation Versus Vagal Stimulation for Post-stroke Hemiplegia: Study Protocol for a Multicenter Randomized Controlled Trial
Background: Hemiplegia is a common complication after a stroke. Studies have shown that traditional medical and rehabilitation treatments are not good for improving patients' motor function, deep brain stimulation (DBS) and vagus nerve stimulation (VNS) can improve the motor function of patients, but there is no comparative study between them. Objectives: This study compares the efficacy and safety of DBS and VNS in the recovery of motor function in patients with post-stroke hemiplegia, determining the best treatment for patients with post-stroke hemiplegia, and providing high-level clinical evidence for patients and clinicians to choose from. Methods/Design: This is a randomized, double-blind, sham-controlled, cross-controlled pilot study. A total of 98 patients with post-stroke hemiplegia are assigned to receive DBS or VNS. After 3 and 6 months of follow-up, all the devices are turned off. After a 2-week washout, the control group is turned on, but the stimulation group is given sham stimulation. After 9 and 12 months of follow-up, all the devices are turned on. Then, at postoperative 15 and 18 months, postoperative neuroimaging and various post-stroke motor-related scores were performed for data collection and analysis. Discussion: We propose a study design and rationale to compare the efficacy and safety of DBS and VNS in patients with post-stroke hemiplegia to provide evidence and reference for implantable neuromodulation in the treatment of post-stroke dysfunction, and to compare the therapeutic effects of DBS and VNS to provide evidence for patient and clinical diagnosis and treatment choices. Study limitations are related to the small sample size and short study period.
Read the detailed description
The incidence of stroke has been more than 20 million stroke patients worldwide, and it has become the third highest-burden disease in the world. The disability rate of stroke is as high as 60-80%. The movement disorder left by the disease is the main reason for the high burden of the disease. At present, there is no particularly obvious and effective treatment measure in clinical practice.
If it is not treated in time, it may lead to permanent disability. The high cost of traditional rehabilitation and the fatigue of rehabilitation training institutions and family commuting makes it difficult for patients to adhere to and the treatment effect is poor. Deep Brain Stimulation (DBS)and vagal nerve stimulation (VNS) therapy have achieved good therapeutic effects in many diseases that were considered difficult to treat in the past, such as Parkinson's, depression, and other diseases, so it is applied to In the treatment of motor function recovery after stroke, many animal experiments and human clinical studies have confirmed its efficacy. However, the efficacy and safety of DBS and VNS in the treatment of poststroke motor dysfunction have not been verified by clinical randomized controlled trials.
The investigators plan to design a multicenter, prospective, randomized, parallel controlled equivalent clinical trial, aiming to explore the efficacy and safety of DBS and VNS in the treatment of motor dysfunction after stroke in the following aspects:(1) improvement rate of hemiplegia after stroke (2) improvement rate of life quality, mental and cognitive status, (3)stimulation parameters, (4) adverse effects. The main purpose of our design of this study was to provide more clinical evidence for the use of DBS and VNS in patients with post-stroke motor dysfunction. The primary objective was to determine the effectiveness and safety of DBS and VNS for improving motor dysfunction in stroke patients. The secondary purpose is to explore the mechanism of DBS and VNS in the treatment of the neurological function of post-stroke motor impairment and the improvement of the quality of life and psychosocial status of patients. According to the inclusion and exclusion criteria, the investigators aimed to collect 98 patients who were diagnosed with stroke and left with motor dysfunction. All patients included in the study will undergo DBS implantation after baseline assessment, and then will be randomly divided into 2 groups at a ratio of 1:1: DBS treatment group and VNS group. After 3 and 6 months of follow-up, all the devices are turned off. After a 2-week washout, the control group is turned on, but the stimulation group is given sham stimulation. After 9 and 12 months of follow-up, all the devices are turned on. The investigators will record standardized videos and/or complete a series of clinical scales (see outcome measures) for all patients at baseline, one month postoperatively, three months postoperatively, six months postoperatively, and one year postoperatively. Then, at postoperative 15 and 18 months, postoperative neuroimaging and various post-stroke motor-related scores were performed for data collection and analysis. Meanwhile, the stimulation parameters and adverse effects will also be documented. Finally, two professional raters will assess the severity at different time points according to those standardized videos in a blind manner. Intention-to-treatment analysis and protocol analysis are both conducted by a professional data analyst.
- Conditions
- Stroke Sequelae, Deep Brain Stimulation, Vagus Nerve Stimulation, Motor Recovery, Stroke, Hemiplegia
- Being tested
- The DBS electrodes are implanted into MLR., The electrodes are implanted into the patient's vagus nerve
- Medical subject headings
- Stroke, Hemiplegia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
The DBS electrodes are implanted into MLR.Procedure or surgery
MLR-DBS#Deep brain stimulation of the mesencephalic locomotor region#The arm will be switched on one month postoperatively for electrical stimulation therapy,exercise training rehabilitation and EMG-triggered neuromuscular stimulation. Specialist doctors will assess the patient's rehabilitation status through the telerehabilitation system every week, and provide guidance on rehabilitation training and electrical stimulation therapy.
The electrodes are implanted into the patient's vagus nerveProcedure or surgery
A pre-surgery assessment was performed. Device implantation was done under general anaesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunnelled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region
| Study group | Role | What they receive |
|---|---|---|
| The DBS electrodes are implanted into MLR. | Experimental | The DBS electrodes are implanted into MLR.MLR-DBS#Deep brain stimulation of the mesencephalic locomotor region#The arm will be switched on one month postoperatively for electrical stimulation therapy, exercise training rehabilitation, and EMG-triggered neuromuscular stimulation. Specialist doctors will assess the patient's rehabilitation status through the telerehabilitation system every week, and provide, and guide on rehabilitation training and electrical stimulation therapy. Device: GPi-DBS devices DBS electrode: 3387 (Medtronic, Minneapolis, MN, USA) or L302 (PINS Medical, Beijing, China) or 1210(SceneRay, Suzhou, China); Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China); Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China). Receives: Procedure: The DBS electrodes are implanted into MLR. |
| The electrodes are implanted into the patient's vagus nerve | Active comparator | The electrodes are implanted into the patient's vagus nerve. A pre-surgery assessment was performed. Device implantation was done under general anesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunneled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region Receives: Procedure: The electrodes are implanted into the patient's vagus nerve |
What is being measured
The primary outcome is the main question the study is designed to answer.
Motor function intervention effect: Fugl-Meyer Assessment Scale (FMA)
Fugl-Meyer Assessment Scale (FMA) was used to measure the motor function of stroke patients. FMA is widely used in clinical motor function assessment and is a quantitative stroke-specific scale used to assess motor function, balance, sensory and joint function in hemiplegic patients. Each of the five domains contains different assessment items, which are scored on a 3-point scale: 0 = unable to perform. 1 = Partially performed, 2 = Fully performed This scale has been found to have good validity and reliability in the stroke population . There are 17 items in total, and the higher the score, the better the motor function.
Measured: Up to 1.5 year postoperatively
Secondary outcomes (5)
Overall improvement of clinical symptoms
The NIHSS score is used to evaluate the degree of neurological deficit in stroke patients. The baseline evaluation can assess the severity of stroke, and the treatment effect can be regularly evaluated after treatment. Scores range from 0 to 42, with higher scores indicating more severe neurological damage. ; Patients with a score of 16 are likely to die; A score of 6 is highly likely to have a good recovery.
Measured: Up to 1.5 year postoperatively
The incidence of surgical complications and side effects
Continuously record the subjects' complications and side effects
Measured: Up to 1.5 year postoperatively
Change of 36-item Short Form General Health Survey (SF-36)
The SF-36 scale is a comprehensive index that reflects the health status of individuals.This scale has 8 dimensions to evaluate health-related quality of life, namely, physical function (PF), role physical (RP), body pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), mental health (MH). Higher score indicates better health status.
Measured: Up to 1.5 year postoperatively
Change of Hamilton Anxiety Scale (HAMA)
HAMA score can better reflect the severity of anxiety. It is composed of two parts, namely, physical anxiety (item 7-13) and mental anxiety (item 1-6, 14). Total score ≥ 29 points: severe anxiety; Total score ≥21 points: there must be significant anxiety; Total score ≥14 points: there must be anxiety; Total score ≥ 7 points: you may have anxiety; Total score < 7 points: there are no symptoms of anxiety.
Measured: Time Frame: Six months postoperatively, and one year postoperatively.
Change of 24-item Hamilton Depression Scale (HAMD)
HAMD score can better reflect the severity of depression. Total score < 7 points: normal; Total score 7-17 points: possible depression; Total score 17-24 points: definitely depression; Total score > 24 points: severe depression.
Measured: Up to 1.5 year postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Nov 2023
- Study start10 Nov 2023 (estimated)
- Primary completion30 Oct 2029 (estimated)
- Study completion30 Oct 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Stroke SequelaeStudies of the same condition, open and under way.
- More trials run by Chinese PLA General HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 98 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chinese PLA General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Zhiqi Mao, Chinese PLA General Hospital
- Investigators
- Zhiqi Mao, PhD, Study director, Chinese PLA General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06121947
- Sponsor's protocol ID
- ChinaPLAGH_Xjp1
- Status last verified
- Nov 2023
- First submitted
- 28 Oct 2023
- Last updated
- 8 Nov 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Xu J, Liu B, Shang G, Liu S, Feng Z, Zhang Y, Yang H, Liu D, Chang Q, Yuhan C, Yu X, Mao Z. Deep brain stimulation versus vagus nerve stimulation for the motor function of poststroke hemiplegia: study protocol for a multicentre randomised controlled trial. BMJ Open. 2024 Oct 8;14(10):e086098. doi: 10.1136/bmjopen-2024-086098.
PubMed 39384245
Study at a glance
From the registry record, last updated by the sponsor on 8 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Study of the Efficacy and Safety of Deep Brain Stimulation Versus Vagal Stimulation for Post-stroke Hemiplegia: Study Protocol for a Multicenter Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT06121947
- Acronym / sponsor ID
- ChinaPLAGH_Xjp1
- Conditions
- Stroke Sequelae, Deep Brain Stimulation, Vagus Nerve Stimulation, Motor Recovery, Stroke, Hemiplegia
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 98 participants (estimated)
- Lead sponsor
- Chinese PLA General HospitalUniversity, hospital or other
- Study start
- 10 Nov 2023 (estimated)
- Primary completion
- 30 Oct 2029 (estimated)
- Study completion
- 30 Oct 2030 (estimated)
- First posted
- 8 Nov 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background: Hemiplegia is a common complication after a stroke. Studies have shown that traditional medical and rehabilitation treatments are not good for improving patients' motor function, deep brain stimulation (DBS) and vagus nerve stimulation (VNS) can improve the motor function of patients, but there is no comparative study between them. Objectives: This study compares the efficacy and safety of DBS and VNS in the recovery of motor function in patients with post-stroke hemiplegia, determining the best treatment for patients with post-stroke hemiplegia, and providing high-level clinical evidence for patients and clinicians to choose from. Methods/Design: This is a randomized, double-blind, sham-controlled, cross-controlled pilot study. A total of 98 patients with post-stroke hemiplegia are assigned to receive DBS or VNS. After 3 and 6 months of follow-up, all the devices are turned off. After a 2-week washout, the control group is turned on, but the stimulation group is given sham stimulation. After 9 and 12 months of follow-up, all the devices are turned on. Then, at postoperative 15 and 18 months, postoperative neuroimaging and various post-stroke motor-related scores were performed for data collection and analysis. Discussion: We propose a study design and rationale to compare the efficacy and safety of DBS and VNS in patients with post-stroke hemiplegia to provide evidence and reference for implantable neuromodulation in the treatment of post-stroke dysfunction, and to compare the therapeutic effects of DBS and VNS to provide evidence for patient and clinical diagnosis and treatment choices. Study limitations are related to the small sample size and short study period.
Detailed description
The incidence of stroke has been more than 20 million stroke patients worldwide, and it has become the third highest-burden disease in the world. The disability rate of stroke is as high as 60-80%. The movement disorder left by the disease is the main reason for the high burden of the disease. At present, there is no particularly obvious and effective treatment measure in clinical practice.
If it is not treated in time, it may lead to permanent disability. The high cost of traditional rehabilitation and the fatigue of rehabilitation training institutions and family commuting makes it difficult for patients to adhere to and the treatment effect is poor. Deep Brain Stimulation (DBS)and vagal nerve stimulation (VNS) therapy have achieved good therapeutic effects in many diseases that were considered difficult to treat in the past, such as Parkinson's, depression, and other diseases, so it is applied to In the treatment of motor function recovery after stroke, many animal experiments and human clinical studies have confirmed its efficacy. However, the efficacy and safety of DBS and VNS in the treatment of poststroke motor dysfunction have not been verified by clinical randomized controlled trials.
The investigators plan to design a multicenter, prospective, randomized, parallel controlled equivalent clinical trial, aiming to explore the efficacy and safety of DBS and VNS in the treatment of motor dysfunction after stroke in the following aspects:(1) improvement rate of hemiplegia after stroke (2) improvement rate of life quality, mental and cognitive status, (3)stimulation parameters, (4) adverse effects. The main purpose of our design of this study was to provide more clinical evidence for the use of DBS and VNS in patients with post-stroke motor dysfunction. The primary objective was to determine the effectiveness and safety of DBS and VNS for improving motor dysfunction in stroke patients. The secondary purpose is to explore the mechanism of DBS and VNS in the treatment of the neurological function of post-stroke motor impairment and the improvement of the quality of life and psychosocial status of patients. According to the inclusion and exclusion criteria, the investigators aimed to collect 98 patients who were diagnosed with stroke and left with motor dysfunction. All patients included in the study will undergo DBS implantation after baseline assessment, and then will be randomly divided into 2 groups at a ratio of 1:1: DBS treatment group and VNS group. After 3 and 6 months of follow-up, all the devices are turned off. After a 2-week washout, the control group is turned on, but the stimulation group is given sham stimulation. After 9 and 12 months of follow-up, all the devices are turned on. The investigators will record standardized videos and/or complete a series of clinical scales (see outcome measures) for all patients at baseline, one month postoperatively, three months postoperatively, six months postoperatively, and one year postoperatively. Then, at postoperative 15 and 18 months, postoperative neuroimaging and various post-stroke motor-related scores were performed for data collection and analysis. Meanwhile, the stimulation parameters and adverse effects will also be documented. Finally, two professional raters will assess the severity at different time points according to those standardized videos in a blind manner. Intention-to-treatment analysis and protocol analysis are both conducted by a professional data analyst.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| The DBS electrodes are implanted into MLR. | Experimental | Procedure: The DBS electrodes are implanted into MLR.The DBS electrodes are implanted into MLR.MLR-DBS#Deep brain stimulation of the mesencephalic locomotor region#The arm will be switched on one month postoperatively for electrical stimulation therapy, exercise training rehabilitation, and EMG-triggered neuromuscular stimulation. Specialist doctors will assess the patient's rehabilitation status through the telerehabilitation system every week, and provide, and guide on rehabilitation training and electrical stimulation therapy. Device: GPi-DBS devices DBS electrode: 3387 (Medtronic, Minneapolis, MN, USA) or L302 (PINS Medical, Beijing, China) or 1210(SceneRay, Suzhou, China); Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China); Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China). |
| The electrodes are implanted into the patient's vagus nerve | Active comparator | Procedure: The electrodes are implanted into the patient's vagus nerveThe electrodes are implanted into the patient's vagus nerve. A pre-surgery assessment was performed. Device implantation was done under general anesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunneled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Meet WHO or international diagnostic criteria for stroke disease;
- The first unilateral supratentorial ischemic or hemorrhagic stroke, the condition is stable after acute treatment of ischemic stroke, the course of disease is 6 months ≤ 1 year, and participate in 2 evaluations (screening and baseline) before enrollment.
- Diagnosed by professional physicians combined with brain CT or magnetic resonance imaging and other imaging techniques;
- Between the ages of 18 and 80, male or female
- The responsible lesion in the unilateral white matter area indicated by cranial CT or MRI
Key exclusion criteria (14 listed)
- Glasgow Coma Scale (GSC) score below 15, Minimum Mental State Examination (MMSE) assessment for dementia indicated, suffering from mental disturbance and unable to cooperate with examination or treatment.
- Motor and sensory disturbances are not induced by stroke, nor by previous ischemic stroke, but stroke induced by trauma, brain tumor, etc.
- Serious comorbidities, such as malignant tumors, primary heart, liver, kidney or hematopoietic system diseases.
- History of cognitive impairment, mental disorder, drug abuse, drug allergy, and alcoholism.
- Infection or rupture of the skin on the forearm or leg.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| The DBS electrodes are implanted into MLR.MLR-DBS#Deep brain stimulation of the mesencephalic locomotor region#The arm will be switched on one month postoperatively for electrical stimulation therapy,exercise training rehabilitation and EMG-triggered neuromuscular stimulation. Specialist doctors will assess the patient's rehabilitation status through the telerehabilitation system every week, and provide guidance on rehabilitation training and electrical stimulation therapy. | Procedure or surgery | The DBS electrodes are implanted into MLR. |
| The electrodes are implanted into the patient's vagus nerveA pre-surgery assessment was performed. Device implantation was done under general anaesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunnelled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region | Procedure or surgery | The electrodes are implanted into the patient's vagus nerve |
Primary outcome
Motor function intervention effect: Fugl-Meyer Assessment Scale (FMA)
Time frame: Up to 1.5 year postoperatively
Fugl-Meyer Assessment Scale (FMA) was used to measure the motor function of stroke patients. FMA is widely used in clinical motor function assessment and is a quantitative stroke-specific scale used to assess motor function, balance, sensory and joint function in hemiplegic patients. Each of the five domains contains different assessment items, which are scored on a 3-point scale: 0 = unable to perform. 1 = Partially performed, 2 = Fully performed This scale has been found to have good validity and reliability in the stroke population . There are 17 items in total, and the higher the score, the better the motor function.
5 secondary outcomes
Overall improvement of clinical symptoms
Time frame: Up to 1.5 year postoperatively
The incidence of surgical complications and side effects
Time frame: Up to 1.5 year postoperatively
Change of 36-item Short Form General Health Survey (SF-36)
Time frame: Up to 1.5 year postoperatively
Change of Hamilton Anxiety Scale (HAMA)
Time frame: Time Frame: Six months postoperatively, and one year postoperatively.
Change of 24-item Hamilton Depression Scale (HAMD)
Time frame: Up to 1.5 year postoperatively
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Nov 2023.
- Derived from this study: PubMed 39384245Xu J, Liu B, Shang G, Liu S, Feng Z, Zhang Y, Yang H, Liu D, Chang Q, Yuhan C, Yu X, Mao Z. Deep brain stimulation versus vagus nerve stimulation for the motor function of poststroke hemiplegia: study protocol for a multicentre randomised controlled trial. BMJ Open. 2024 Oct 8;14(10):e086098. doi: 10.1136/bmjopen-2024-086098.
- Individual participant dataSharing planned: Undecided
Related trials for Stroke Sequelae
Enrolling by invitationObservational study
Psychometric Study of the Spanish Version of Two Upper Limb Assessment Scales in Chronic Stroke
Chronic Stroke
Not yet recruitingPhase 2
ALT001 in Patients With Ischemic Stroke in the Sequelae Stage
Ischemic Stroke in the Sequelae Stage
Not yet recruiting
Effects of Different-Frequency Electroacupuncture on Suprahyoid Muscles in Post-Stroke Dysphagia: Efficacy and Neural Networks
Stroke Sequelae, Deglutition Disorders
Active, not recruitingObservational study
A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development
Spasticity as Sequela of Stroke
Recruiting
TDCS to Improve Post-Stroke Cognitive Impairment
Stroke, Stroke Sequelae
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Zhiqi Mao, PhD study director
Chinese PLA General Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing The DBS electrodes are implanted into MLR. and The electrodes are implanted into the patient's vagus nerve in people with Stroke Sequelae and Deep Brain Stimulation, run by Chinese PLA General Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 8 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Zhiqi Mao, PhD (8618910155994, markmaoqi@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Motor function intervention effect: Fugl-Meyer Assessment Scale (FMA) (time frame: Up to 1.5 year postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06121947, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Nov 2023.